AbbVie Inc. (ABBV): Among the Best S&P 500 Dividend Stocks to Buy Now
Stock market investors have enjoyed strong annual returns over the past two years, but analysts caution that 2025 may not ...
24/7 Wall St12h
Market Correction Wake-Up Call? 4 Dependable High-Yield Dividend Kings to the Rescue
Growth and income investors who want to stay invested but shift to a more balanced approach may want to look at the Dividend ...
Top Monthly Winners: AbbVie, Philip Morris, and More
In February 2025, stock markets fell on average. The S&P 500 (SPY) fell by 1.27%, due mostly to a decline in technology stocks. Investors reallocated their holdings into the drug sector. AbbVie (ABBV) ...
Zacks.com on MSN21h
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin Drug
AbbVie ABBV announced that it has entered into a licensing agreement with Denmark-based biotech Gubra for the latter’s ...
Crain's Chicago Business22h
AbbVie enters obesity drug market with Danish drugmaker
AbbVie has signed a licensing deal with Gubra A/S to develop an obesity drug, marking the North Chicago company's first foray ...